Middle East and Africa Veterinary Parasiticides Market Size, Share & Trends Analysis Report By Product Type (EndoparasiticidesAnthelminticsAntiprotozoals, EctoparasiticidesInsecticidesAcaricides, EndectocidesMacrocyclic lactones (e.g., ivermectin, moxidectin)Isoxazolines), By Animal Type (Companion AnimalsDogsCatsOthers (birds, rabbits, etc.), Livestock AnimalsCattleSheep and GoatsPoultrySwineOthers (horses, camels, etc.)), By Country (Brazil, Mexico, Argentina, Chile, Colombia) and Forecast, 2026-2034

Middle East and Africa Veterinary Parasiticides Market Trends

Shift Toward Broad-Spectrum, Convenient and Longer-Acting Parasite Protection

Innovation is shifting toward combination, broad-spectrum, chewable, and longer-duration therapies designed to improve compliance. Zoetis reports investment exceeding USD 6 billion in R&D since 2013, more than 2,000 new products and lifecycle innovations over 13 years, around 300 product lines across 8 species, and research spanning 90 therapeutic targets. Its parasiticide pipeline specifically emphasizes next-generation long-acting solutions.

Middle East and Africa Veterinary Parasiticides Market Drivers

High Parasite Burden and Livestock-Health Requirements Accelerate Veterinary Parasiticides Market Growth

Persistent parasite exposure across large livestock populations supports recurring treatment cycles. Research covering 8,717 cattle identified 3,211 positive coccidiosis cases (36.84%), while 1,316 of 2,148 goats (61.26%) and 895 of 1,916 sheep (46.71%) tested positive. In addition, North African countries including Egypt collectively hold around 95 million sheep and goats, equivalent to 13% of Africa's small-ruminant population and 4% globally, creating a substantial addressable animal-health base.

Middle East and Africa Veterinary Parasiticides Market Restraints

Fragmented Veterinary Access and Livestock Economics Limit Treatment Consistency

Treatment penetration remains constrained where livestock ownership is dispersed and veterinary infrastructure is uneven. Small-ruminant systems can experience annual mortality rates of approximately 25–40%, while disease, nutrition, affordability, and access collectively influence farmers' willingness to maintain preventive treatment schedules. Africa's livestock sector historically contributes around 30% of agricultural production value, making animal health economically important but also exposing parasiticide purchasing to farm-income and input-cost pressures.

Challenges in Middle East and Africa Veterinary Parasiticides Market

Cross-Border Disease Exposure and Diverse Parasite Profiles Complicate Control

Africa, Asia, and the Middle East collectively host more than 80% of the world's small-ruminant population, increasing the complexity of disease surveillance and animal movement management. PPR alone produces estimated annual losses of approximately USD 1.2–1.7 billion, while endemic FMD losses are estimated at USD 6.5–21 billion. These pressures compete for veterinary budgets while requiring integrated surveillance, preventive treatment, vaccination, and biosecurity programs.

Middle East and Africa Veterinary Parasiticides Market Segmentation

The industry is segmented by product type, animal type, mode of administration, distribution channel, and end user. Within the supplied quantitative product segmentation, endoparasiticides dominate at approximately 52.18% of 2026 revenue, compared with 31.47% for ectoparasiticides and 16.35% for endectocides.

By Product Type

Endoparasiticides are the largest category, increasing from USD 599.81 million in 2025 to USD 631.84 million in 2026 and USD 957.97 million by 2034 at 5.34% CAGR. The category includes anthelmintics and antiprotozoals and represents more than half of supplied 2026 product revenue.

Ectoparasiticides, including insecticides and acaricides, are the fastest-growing category at 5.66% CAGR, versus 5.38% for endectocides. Ectoparasiticides advance from USD 381.14 million in 2026 to USD 592.06 million in 2034, while endectocides rise from USD 197.99 million to USD 301.10 million.

By Animal Type

Companion animals comprise dogs, cats, birds, rabbits, and other pets, while livestock includes cattle, sheep and goats, poultry, swine, horses, and camels. Quantitative revenue and CAGR splits by animal type were not supplied; therefore, no unsupported market values are assigned. Supporting epidemiological evidence nevertheless shows parasite prevalence of 36.84% in cattle and 61.26% in goats, demonstrating the treatment intensity associated with livestock applications.

By Mode of Administration

Administration comprises oral tablets, chewables and liquids; topical spot-ons, sprays and pour-ons; injectables; and other formulations. Quantitative segment revenue and CAGR data were not supplied for these categories. Industry innovation increasingly favors convenient dosing: Zoetis' portfolio spans roughly 300 product lines across 8 species, while its R&D platform covers 90 therapeutic targets and explicitly prioritizes longer-acting parasiticide formats.

Middle East and Africa Veterinary Parasiticides Market Countries Outlook

The supplied country dataset totals USD 1,210.42 million in 2026 and USD 1,843.44 million in 2034. The UAE, South Africa, and Saudi Arabia collectively account for approximately 80.56% of the 2026 total, demonstrating concentrated commercial activity across the leading markets.

United Arab Emirates

The UAE generates USD 485.98 million in 2026, approximately 40.15% of the supplied regional total, and reaches USD 735.70 million by 2034 at 5.32% CAGR. Preventive animal-health infrastructure is increasingly digitalized, with 360 disease reports recorded through the national notification system in 2025.

Saudi Arabia

Saudi Arabia contributes approximately 15.14%, with revenue increasing from USD 183.23 million in 2026 to USD 284.62 million by 2034. Its 5.66% CAGR is the highest among the supplied countries, supported by livestock protection and an expanding companion-animal economy.

Egypt, Nigeria and Turkey

Egypt rises from USD 98.51 million to USD 152.79 million at 5.64% CAGR; Nigeria increases from USD 74.95 million to USD 112.94 million at 5.26%; and Turkey advances from USD 61.86 million to USD 95.72 million at 5.61%. Together, the three countries contribute approximately 19.44% of supplied 2026 revenue.

Top players in Middle East and Africa Veterinary Parasiticides Market

• Zoetis Inc.
• Boehringer Ingelheim
• Elanco Animal Health
• MSD Animal Health
• Ceva Santé Animale
• Virbac
• Vetoquinol
• Dechra Pharmaceuticals
• Norbrook Laboratories
• Chanelle Pharma
• Bimeda
• HIPRA

The competitive environment includes at least 12 notable international animal-health manufacturers operating across companion and livestock therapeutics. Company-level regional revenue shares for 2025 or 2026 were not included in the mandatory dataset and are not estimated to avoid creating unsupported percentages.

Top Company

• Zoetis Inc. 

 regional company share: not publicly quantified in the supplied data (%). Zoetis maintains strong positioning through broad-spectrum companion-animal parasiticides and continued lifecycle innovation. The company reports more than USD 6 billion invested in R&D since 2013, 2,000+ product/lifecycle innovations over 13 years, and around 300 product lines across 8 species. Its 2025 performance also showed companion-animal sales increasing 7% reported, with parasiticides contributing to growth.

Recent Developments in Middle East and Africa Veterinary Parasiticides Market

• 2026: Zoetis reported that Q4 2025 companion-animal product sales increased 7% reported and livestock sales increased 9% reported, with parasiticides contributing to companion-animal performance.
• 2025: Elanco announced expanded Credelio Quattro and Credelio labels, while citing more than 422,000 canine Lyme disease cases recorded during the year in the referenced U.S. tracker.
• 2025: WOAH and FAO renewed PPR-eradication efforts; PPR has spread to more than 70 countries and can cause morbidity and mortality approaching 100% in naïve populations.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period, and 2026–2034 as the forecast window. Mandatory supplied values were retained as the primary quantitative source: the country table reports USD 1,210.42 million for 2026 and USD 1,843.44 million for 2034, while the separately supplied product table reports USD 1,210.97 million and USD 1,851.13 million, respectively. These two source totals were intentionally not reconciled or altered; shares were calculated only against the corresponding table total. Secondary evidence from FAO, WOAH, company disclosures, and animal-health research was used exclusively for epidemiology, livestock context, technology, competitive developments, and qualitative validation rather than replacing the mandatory forecast dataset.